ACLARA to Host Investor Briefing and Webcast at ASCO Annual Meeting Monday June 7, 2004 at 7:00 A.M. Central time
03 Juni 2004 - 3:00PM
PR Newswire (US)
ACLARA to Host Investor Briefing and Webcast at ASCO Annual Meeting
Monday June 7, 2004 at 7:00 A.M. Central time MOUNTAIN VIEW,
Calif., June 3 /PRNewswire-FirstCall/ -- ACLARA BioSciences
(NASDAQ:ACLA) will conduct an investor briefing to provide an
overview of the company's protein-based molecular diagnostics
technology, the eTag(TM) System, at the American Society of
Clinical Oncology Meeting (ASCO) on Monday, June 7 at 7:00 a.m.
Central Time at the Embassy Suites Hotel, 315 Julia Street, New
Orleans in the Andrew Jackson Board Room. The briefing will be
hosted by Thomas Klopak, ACLARA's chief executive officer and Dr.
Sharat Singh, ACLARA's chief technical officer and inventor of the
eTag technology. Members of the Company's Scientific Advisory
Board, Dr. David Agus, M.D., and Dr. Carlos Arteaga, M.D., will
also be available to answer questions regarding their respective
scientific work. Dr. Agus, Research Director at the Louis Warschaw
Prostate Cancer Center at Cedars-Sinai Medical Center and Assistant
Professor of Medicine at UCLA, is researching the various factors
that influence cancer development, progression and response to
treatment. Dr. Arteaga, Professor of Medicine and Cancer Biology
and Director of the Breast Cancer Research Program of the
Vanderbilt-Ingram Cancer Center at Vanderbilt University School of
Medicine is distinguished for his studies of the HER2 receptor.
Investor Briefing Webcast and Conference Call Details Those wishing
to participate in the Investor Briefing via live teleconference
should call 800-289-0494 several minutes before 7 a.m. Central
Time, Monday June 7. In addition, the audio and slide presentations
from the briefing will be simultaneously broadcast over the
Internet and will be available to investors, news media and the
general public. The live and archived webcast can be accessed by
going to Investor Relations section at http://www.aclara.com/ and
clicking on the Conference Calls link. The webcast will be archived
on the ACLARA website. For those who are not able to access the
live conference, an audio replay will be available until Wednesday
June 9, 2004 by dialing 888-203-1112 (U.S.) or 719-457-0820
(international) and giving the following confirmation code: 643288
for access. About ACLARA Founded in 1995, ACLARA is a biotechnology
company working to provide physicians and researchers products and
services to make personalized medicine a reality through its
protein-based assay technology -- the eTag(TM) System. ACLARA is
dedicated to unlocking the power of pathway biology to accelerate
the development of next-generation targeted therapeutics,
recognizing the most appropriate patients for approved therapies
and identifying the highly-specific, protein-based biomarkers that
will enable physicians to create truly personalized treatment
regimens for patients suffering from cancer and other
life-threatening disorders. ACLARA is commercializing its
proprietary eTag System to enhance and accelerate drug discovery
research and the preclinical and clinical development of targeted
therapeutics. ACLARA's technology may also enable the development
of highly-specific, protein-based diagnostics capable of providing
physicians with a powerful tool for creating personalized treatment
regimens for patients suffering from serious and difficult-to-treat
cancers. For more information on ACLARA please visit the Company's
web site at http://www.aclara.com/ . Forward-Looking Statements All
statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934 as amended. Such forward-looking statements
are subject to factors that could cause actual results to differ
materially for ACLARA from those projected. Those factors include
risks and uncertainties relating to the performance of our
products, anticipated progress in commercialization of our eTag(TM)
assay system; the potential for use of our eTag assays in clinical
development programs; the potential for use of our eTag assays as
diagnostic tests; our ability to successfully conduct clinical
studies and the results obtained from those studies; our ability to
establish reliable, high-volume operations at commercially
reasonable costs; expected reliance on a few customers for the
majority of our revenues; actual market acceptance of our products
and adoption of our technological approach and products by
pharmaceutical and biotechnology companies; our estimate of the
size of our markets; our estimates of the levels of demand for our
products; our ability to develop organizational capabilities
suitable for the further development and commercialization of our
eTag assays; the ultimate validity and enforceability of our patent
applications and patents; the possible infringement of the
intellectual property of others; technological approaches of ACLARA
and our competitors; our pending merger with ViroLogic, Inc.,
including the risk that the closing conditions or the merger may
not be satisfied and the merger may not be completed, and costs
related to the proposed merger; and other risk factors identified
in our Form 10-Q for the quarter ended March 31, 2004 as filed with
the Securities and Exchange Commission. DATASOURCE: ACLARA
BioSciences CONTACT: investors, Alfred Merriweather, VP, Finance
and CFO of ACLARA BioSciences, +1-650-210-1200, or ; or Steven
Cragle or Jennifer Viera of Schwartz Communications,
+1-415-512-0770, or +1-781-684-0770, or at ASCO, +1-415-845-1256,
or +1-617-875-7506, or , for ACLARA BioSciences Web site:
http://www.aclara.com/
Copyright
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über Aclara Biosciences, (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Aclara Biosciences, (MM) News-Artikel